Fig 1.
A flowchart for determination of immune-related adverse events involving the thyroid gland (thyroid irAEs).
Determination and classifications were based on data of thyroid function tests.
Table 1.
Characteristics of patients with subclinical and overt thyroid irAEs and comparisons to those without thyroid irAEs.
Table 2.
Odds ratio for overt thyroid irAE development.
Fig 2.
The representative clinical course of overt thyroid irAE.
Regarding 17 patients with overt thyroid irAEs and thyrotoxicosis, the medians of the results of thyroid function tests and doses of levothyroxine replacement were plotted. For clarity, the values of 3, 9, 15, and 21 weeks in patients with malignant melanoma were integrated into those of 4, 10, 16, and 22 weeks, respectively.
Fig 3.
Kaplan-Meier curves of overall survival according to thyroid irAEs.
Patients censored within 1 month from the first administration of nivolumab were excluded from each cohort. (A) Results in the total cohort; (B) results of comparisons between the overt thyroid irAE group and the subclinical thyroid irAE group in the total cohort; (C) results in the cohort of lung cancer; (D) results in the cohort of malignant melanoma. HR, hazard ratio; CI, confidence interval.
Fig 4.
Kaplan-Meier curves of progression-free survival according to thyroid irAEs.
Patients censored within 1 month from the first administration of nivolumab were excluded from each cohort. (A) Results in the total cohort; (B) results of comparisons between the overt thyroid irAE group and the subclinical thyroid irAE group in the total cohort; (C) results in the cohort of lung cancer; (D) results in the cohort of malignant melanoma.